Reappraising the clinical impact of mepolizumab

Brian J. Lipworth (Lead / Corresponding author), Sunny Jabbal

Research output: Contribution to journalLetter

29 Downloads (Pure)
Original languageEnglish
Article numbere20
Number of pages1
JournalLancet
Volume5
Issue number6
Early online date26 May 2017
DOIs
Publication statusPublished - Jun 2017

Cite this

@article{4f73a65cb8f0479da57e841c1e8a72c7,
title = "Reappraising the clinical impact of mepolizumab",
author = "Lipworth, {Brian J.} and Sunny Jabbal",
note = "BJL reports grants from AstraZeneca and Sanofi, and grants, personal fees, and other from Chiesi and Teva, relevant to the submitted work; and personal fees from Dr Reddys, Cipla, Lupin, and Sandoz, grants and personal fees from Meda, grants, personal fees, and other from Boehringer Ingelheim, and grants from Almirral, outside of the submitted work. His son is an employee of Boehringer Ingelheim. SJ reports personal fees and non-financial support from Chiesi and AstraZeneca, and non-financial support and other from Napp, relevant to the submitted work; and personal fees and non-financial support from Pfizer, outside of the submitted work",
year = "2017",
month = "6",
doi = "10.1016/S2213-2600(17)30183-2",
language = "English",
volume = "5",
journal = "Lancet",
issn = "0140-6736",
number = "6",

}

Reappraising the clinical impact of mepolizumab. / Lipworth, Brian J. (Lead / Corresponding author); Jabbal, Sunny.

In: Lancet, Vol. 5, No. 6, e20, 06.2017.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Reappraising the clinical impact of mepolizumab

AU - Lipworth, Brian J.

AU - Jabbal, Sunny

N1 - BJL reports grants from AstraZeneca and Sanofi, and grants, personal fees, and other from Chiesi and Teva, relevant to the submitted work; and personal fees from Dr Reddys, Cipla, Lupin, and Sandoz, grants and personal fees from Meda, grants, personal fees, and other from Boehringer Ingelheim, and grants from Almirral, outside of the submitted work. His son is an employee of Boehringer Ingelheim. SJ reports personal fees and non-financial support from Chiesi and AstraZeneca, and non-financial support and other from Napp, relevant to the submitted work; and personal fees and non-financial support from Pfizer, outside of the submitted work

PY - 2017/6

Y1 - 2017/6

UR - http://www.scopus.com/inward/record.url?scp=85019717583&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(17)30183-2

DO - 10.1016/S2213-2600(17)30183-2

M3 - Letter

VL - 5

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 6

M1 - e20

ER -